Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D000077764:Dronedarone; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; C502994:saxagliptin; D000068799:Prasugrel Hydrochloride; D000077764:Dronedarone; D000638:Amiodarone; D000218:Adamantane